Medicago claims to have a viable vaccine candidate for COVID-19

13 March 2020
coronavirus_structure_large

While most Japanese pharma companies were shedding capital value by as much as 7% today, Mitsubishi Chemical (TYO: 4188) closed up 3.48% at 625 yen on the news that one of its units had developed a vaccine against the novel coronavirus.

Canada-based biotech firm Medicago, a subsidiary of Mitsubishi Tanabe Pharma, on Thursday announced it had successfully produced a virus-like particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene.

Production of the VLP is the first step in developing a vaccine for COVID-19 which will now undergo pre-clinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the appropriate health agencies to initiate human trials of the vaccine by summer (July/August) 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology